Planned listing on the London Stock Exchange


The Board has decided to start the process to list the ImmunoPharma-shares on the London Stock Exchange (AIM or Standard). The work has already started to identify and partner up with the investment bank, law firm, PR-company to secure a best possible outcome for the shareholders.

The plan is also to strengthen the management with a new CFO and Investor Relation responsible as part of the IPO-process. The search for this new person will be initiated in August together with a head hunting company.